Programme 2019
Nordic Precision Medicine Forum
18-19 March 2019, Stockholm

Denotes a link to the speaker's bio page.

Scroll down for the full agenda or download the programme in PDF format.
For any enquiries about speaking opportunities or if you have an interest in hosting one of our workshops please email Amanda Rafferty
DAY 1 - Monday March 18, 2019
Registration and Networking Lunch
Welcome and Opening Remarks from the Chair
13:10 - 13:35
Keynote Address: Advancing Personalised Medicine Across Europe: Priorities & Opportunities

 Irene Norstedt, Head of the Innovative and Personalised Medicine Unit, DG Research and Innovation, European Commission

13:35 - 14:55
Exploring the Future Direction of Precision Medicine: What We Hope to Achieve and Required Next Steps

A panel of expert speakers from across the Nordic region will share their views on what has been achieved to date in the implementation of precision medicine; where they believe it is heading in the next 5 years; and where the focus needs to be in order to achieve key aims and objectives.

The presentations will be followed by an in-depth Q&A discussion; delegates are invited to ask questions and share their own views.


 Dr Kári Stefánsson, President, Chairman, CEO and Co-Founder, deCODE Genetics

 Professor Dag Erik Undlien, Department of Medical Genetics, Oslo University Hospital

 Paul Jones Population Genomics, illumina

14:55 - 15:25
Refreshments and Networking
Delegates now move to their chosen break-out session
Interactive Break-Out Sessions
These focused, interactive sessions give you the opportunity to discuss a key topic of interest to you in a more participative format. Each session will be led by a facilitator who will lead the discussion and encourage maximum debate and sharing of ideas.

A. Functional Precision Cancer Medicine - Moving Beyond Genomics

 Professor Dr Janne Lehtiö, Professor, Karolinska Institutet & Scientific Director, SciLifeLab

 Päivi Östling, Associate Professor, Co-Principal Investigator, Kallioniemi Research Group, SciLifeLab

B. An Industry Interface into Population Genomics at Scale

Industry has a critical role to play as countries around the world initiate Population Genomics programmes aiming to deliver precision medicines into more personalised healthcare systems. This session will look at how to balance industry requirements with other key stakeholder groups who also have a critical role to play in preparing healthcare systems for a genomic medicine future.

 Paul Jones Population Genomics, illumina

C. Pharmacogenetics in Clinical Practice: Hurdles to Overcome & Challenges to Solve

In this workshop, challenges encountered in clinical practice in the implementation of pharmacogenetics will be discussed, such as the degree of quality control needed, ethical aspects, legal issues, SNPs to analyse, pros & cons of specific DNA genotyping approaches, how to report, who to inform on the outcome of test results, insurance company aspects, the role of the GP and specialist, role of the pharmacist, patient empowerment and how to deal with new insights in the field.

 Prof. Dr. Ron HN van Schaik, Professor of Pharmacogenetics,Erasmus University Medical Center

D. Polygenic Risk Profiling for Complex Disease

 Professor Mark McCarthy, Professor of Diabetic Medicine, Nuffield Dept of Medicine &Group Head, Wellcome Trust Centre for Human Genetics,University of Oxford

E. A New Era of “Broadband” Sequencing to Realise the Full Benefits of Genomic Information

MGI's newest sequencing platform, MGISEQ-T7, can deliver a maximum data output 6Tb per day, double the throughput currently on the market. MGISEQ-T7 is built with innovative quadruple flow cell staging that allows simultaneous but independent operation of 1 to 4 flow cells in a single run. With MGI's single tube Long Fragment Read (stLFR) technology, the platform enables both long fragment read data of up to 300kb and short read data at 5G (5 billion) reads per flow cell, as well as multiple applications, in the same run on the same instrument. With its breakthrough technologies, MGI advances not only sequencing throughput, but also bandwidth and quality.

This workshop will showcase the MGISEQ-T7 and its capabilities, enabling participants to gain a better understanding of this new era of “broadband” sequencing. Two speakers are users of MGI platforms and would like to share their sequencing projects with us.

A New Era of "Broadband" Sequencing: MGISEQ-T7 Sequencer and Efficient Long Single Molecule Sequencing

  Jingjing Wang, Senior Product Manager, MGI Tech

A Mammalian Brain Atlas with Transcriptomics Data using Next Generation MGI Sequencing

  Dr Mathias Uhlén, Professor of Microbiology, KTH Royal Institute of Technology

A Deeper Understanding of Regenerative Medicine using Transcriptomics and Genomics data from MGI Sequencing

  Prof Dr Yonglun Luo (Alun), Executive Director, Lars Bolund Institute of Regenerative Medicine (LBI), BGI & Associate Professor, Department of Biomedicine, Aarhus University

Genomic Approaches – and Vastly More  - to Overcome Chemoresistance in Ovarian Cancer

  Rainer Lehtonen, Senior Researcher, University of Helsinki

MGI Global Sequencer User Program

  Pingfei Xu, General Manager, MGI Europe

* please note session E only begins at 15.15 until 16.35

Reconvene in main conference room
Panel Session Led by Apotekarsocieteten: Drug Development for Precision Medicine

Moderator: Per Wessman, Head of Section Formulation Development, RISE Research Institutes of Sweden

This session, led by Apotekarsocieteten, the Swedish Pharmaceutical Society, will comprise of two presentations on drug development for precision medicine, followed by a panel debate.

  • Manufacturing Concepts for Realization of Personalised / Precision Medicine – Advances & Future Directions

 Staffan Folestad, Director of Science & Innovation, Pharmaceutical Technology & Development, AstraZeneca

  • Precision Medicine for Children

 Mattias Paulsson, Hospital Pharmacist, Uppsala University Hospital

  • Panel Debate: Important perspectives for the future in precision medicine - regulatory aspects, pharmaceutical manufacturing (processes, formulation and preparation technologies)

 Staffan Folestad, Director of Science & Innovation, Pharmaceutical Technology & Development, AstraZeneca

  Dr Karin Meyer, CEO, Swedish Pharmaceutical Society

 Mattias Paulsson, Hospital Pharmacist, Uppsala University Hospital

 Anna Ridderstad Wollberg, Senior Project Manager, Focus Area Manager New Therapies på RISE Research Institutes of Sweden, Stockholm

Closing remarks from the Chair followed by Complimentary Networking Drinks Reception
DAY 2 - Tuesday March 19, 2019
Welcome Refreshments and Networking
Opening Remarks from the Chair
Examining the Influence of Current Regulatory Frameworks in Facilitating the Progress & Implementation of Precision Medicine
  • Identifying the current legal, regulatory and ethical obstacles restricting the advancement of precision medicine
  • Exploring ways in which regulatory frameworks need to adapt to overcome these obstacles, and enable innovation and delivery
  • Examining how the disease and drug classification system could change to enable a broader, biological approach
  • Outlining the regulatory and ethical perspective with regards to data access and sharing and the use of AI in precision medicine

 Liisa-Maria Voipio-Pulkki, Director General & Chief Medical Officer, Ministry of Social Affairs and Health, Finland

 Isabelle Budin Ljøsne, Senior Advisor, Norwegian Institute of Public Health

 Dr Steffen Thirstrup, Director, NDA Regulatory Advisory Board, NDA Advisory Services & Professor, Faculty of Health Sciences, University of Copenhagen

Q & A Discussion
Morning Refreshments & Networking
The programme will now split into 2 tracks. Delegates are invited to choose the track they would like to attend.
Leveraging the Power of “Big Data” and Technology in Precision Medicine
One of the biggest challenges to advancing precision medicine is managing the huge volumes of data being created. Appropriate bioinformatic methods for managing, integrating, sharing and analysing complex biological data are required to enable reinforcement of commonalities, reduction of “noise” and identification of the right clinical result.
Exploring the Benefits within Precision Medicine of Combining Genomic Profiling (Foundation Medicine) with Outcome Data (Flatiron) to Create a Clinicogenomics Database

 Eva Flahavan, RWD Oncology, Personalised Healthcare, Roche

11.05 Data Integration: Examining Statistical Methods for the Exploration and Integration of Heterogeneous Biological Data Sets
  • Identifying trends or patterns in one single data set (methods around Principal Component Analysis)
  • Extracting common information from two or more biological/omics datasets acquired on the same samples or patients (PLS related methods)
  • Classifying samples or patients based on one or more biological/omics datasets (supervised analysis, PLS-DA)
  • Selecting the most relevant variables involved in the relationships between several datasets (sparse variant or previous methods)

Developing novel methods for multi-omics data integration to extract biologically relevant information (new developments around kernel methods)

 Sébastien Déjean, Research Engineer, Institut de Mathématiques de Toulouse, University of Toulouse III - Paul Sabatier

Data Sharing: Overcoming the Legal, Technical and Human Obstacles to Data Sharing
  • Understanding actual vs perceived barriers to the sharing of genomic and health data:
    • working with relevant stakeholders to influence and overcome these barriers
  • Examining the extent to which the introduction of GDPR has impacted on the accessing and sharing of healthcare data, and how this can be managed
  • Managing patient privacy concerns regarding healthcare data sharing:
    • finding and communicating the balance between patient protection vs scientific discovery
  • Effectively linking health-data registers to establish a research database and facilitate shared decision-making
  • Exploring the use and potential of blockchain-based data sharing and access

 Erik Steinfelder, Director General, BBMRI-ERIC

Applying Artificial Intelligence to Biomedical Data: Challenges & Solutions
  • Exploring how AI and machine learning can facilitate the development of complex, digital biomarkers for the objective assessment of disease progression
  • Using the potential of AI to overcome traditional bottle-necks in new drug discovery and development

 Behrooz Torabi Moghadam, Department of Immunology, Genetics and Pathology, Uppsala University & Co-Founder & CEO, Denapsis Artificial Intelligence

Q & A Discussion
Networking Lunch
Biomarker Development & Diagnostics

Validated, predictive biomarkers are key to the further advancement of precision medicine, and the bridge between research and clinical practice. However almost 90% of biomarkers identified cannot be used as they have not been validated in clinical trials. This session will look at the future development of biomarkers, how their use in clinical practice can be facilitated, as well as new diagnostic techniques for disease prediction and prognosis.

Exploring Measures to Enhance & Accelerate Biomarker Discovery & Validation Processes to Improve their Effective Transition into Clinical Use

 Tobias Sjöblom, Professor, Department of Immunology, Genetics and Pathology, Uppsala University & Director, Research Infrastructure, Biobank Sweden

Developing Pharmacogenomic Biomarkers for Personalised Drug Therapy

Pharmacogenetics: A DNA passport for medication for every person?

DNA analysis to guide drug treatment is gaining in interest and clinical use. But how far are we today from using pharmacogenetics information in daily practice? This presentation will consider the following questions: What can we do now? What are the limitations? What are the current challenges? What is the next step in personalized medicine with respect to using our DNA information?

 Prof. Dr. Ron HN van Schaik, Professor of Pharmacogenetics,Erasmus University Medical Center

Translating Genotype Array Data into Pharmacogenomic Reports and Polygenic Risk Scores
  • Exploring the benefits of using polygenic risk scoring for multi-factorial complex diseases
  • Assessing the potential of polygenic risk scoring as a clinical tool for risk prediction or prognosis:
    • identifying the challenges to be overcome and further research required
    • likely timescales for adoption into clinical practice

 Lili Milani, Professor & Head of Personalized Medicine, Estonian Genome Centre, University of Tartu

Genomics and the Future of Precision Medicine

 Carolina HaefligerVP Head CVRM Precision Medicine Unit, Precision Medicine and Genomics, AstraZeneca

Q & A Discussion
Networking Lunch
The afternoon session will continue in 2 tracks. Delegates are again invited to choose which of the tracks they would like to attend
Advancing Precision Medicine Through Partnerships, Collaboration & Funding Initiatives

The effective implementation of precision medicine needs collaborative approaches, both national and cross-border. Identifying stakeholders, bringing them together, and finding appropriate financial mechanisms are all key elements for success. Examples of innovative collaborative projects for advancing precision medicine will be presented here.

Accelerating new breakthroughs in disease prevention, diagnosis, and treatment through exceptional public-private collaboration: The FinnGen project

 Anu Jalanko, FinnGen Project Manager, Institute for Molecular Medicine Finland (FIMM)

Open Targets: An innovative, large-scale, multi-year, public-private collaboration to transform drug discovery and more effectively target disease

 Ian Dunham, Scientific Director, Open Targets, The European Bioinformatics Institute (EMBL-EBI)

The AZ BioVentureHub: Realising the Potential of Nordic Life Sciences Through Innovative Collaboration

 Dr Magnus R. Björsne, Chief Executive Officer, AstraZeneca BioVentureHub

The Danish National Genome Center: Implementing the Next Steps of Development

The Danish National Genome Center is about to be established with the primary task of laying the foundation for the development of better diagnostics and more targeted treatments using whole genome sequencing. It will develop state of the art infrastructure to enable analysis of big biomedical heterogenous data to provide personalised medicine solutions.

This presentation will give a first insight into the build-up phase, the political process, the new infrastructure and its implementation.

 Peter Løngreen, Acting Director General, Danish National Genome Center

Q & A Discussion
Advancing Precision Medicine Through Multi-Omics Strategies

Genomics studies still contribute the vast majority of precision medicine-based data. However, it is being increasingly recognised that it is not enough to just look at DNA, and instead it is necessary to understand the whole-body narrative. Taking a system biology approach and examining multiple -omics, using information from the genome, proteome, metabolome and transcriptome to identify critical drivers and pathways of disease is being increasingly used to develop personalised medicine strategies.

Developing Integrated Proteomic and Genomic Strategies for Biomarker Discovery & Validation

 Anders MälarstigResearcher, Karolinska Institutet & Director Target Science & Technologies, Pfizer Worldwide Research & Development

Proteomics: Exploring how Protein Biomarker-Based Strategies can Influence & Drive a Precision Medicine Approach

 Dr Mathias Uhlén, Professor of Microbiology, KTH Royal Institute of Technology

Metabolomics-Based Methods for Early Disease Diagnostics

 Professor Matej OresicGroup Leader in Systems Medicine, Turku Centre for Biotechnology, University of Turku & Visiting Associate Professor, School of Medical Sciences,Örebro University

Using an Integrated Multi-Omics Approach to Enable Detailed Molecular Characterisation

 Professor Zsolt Illés, Department of Neurology, Odense University Hospital (OUH) & Institute of Clinical Research, University of Southern Denmark (SDU)

Q & A Discussion
Afternoon Refreshments & Networking
A Final Plenary Session will Conclude the Afternoon
Making It A Reality: Effectively Translating Precision Medicine Research Into Clinical Practice
Translating Genomic Data into Actionable Insights that can be Used in Clinics
  • Optimising national quality registers to create a decision-making support framework based on genomic data
  • Integrating technology with existing healthcare databases to give better patient knowledge and insight
  • Exploring how we can turn broad genomic profiling into information that can be used quickly and easily for patients’ benefit in clinics

 Richard Rosenquist Brandell, Professor of Clinical Genetics, Department of Molecular Medicine and Surgery, Karolinska Institutet, Senior Physician, Clinical Genetics,Karolinska University Hospital, & Project Leader, Genomics Medicine Sweden

Physician’s Perspective: Using Precision Medicine Research in Practice for Patients’ Benefit
  • Detailing how we use the data currently available to us
  • Outlining what we would like from research and the information that is most beneficial to us in consulting with, and treating, patients
  • Effectively communicating new advances in research, trials or drug testing – what information and evidence we need to be convinced of their value

 Andreas Pahle, Board Member, Norwegian College of General Practice & Head of the Digital Health and Personalised Medicine Group, Norwegian College of General Practice & General Practitioner, Bolteløkka Medical Centre

Presentation co-authored by:

 Henrik Vogt, Centre for Medical Ethics,Institute of Health and Society, University of Oslo, General Practice Research Unit, Dept of Public Health, Norwegian University of Science & Technology & General Practitioner, Ullevål Hageby Health Center, Oslo

Patient Perspective: Patients as a Driving-Force to Advance Precision Medicine

 Dr Bettina Ryll,ESMO Patient Advocates Working Group & Founder, Melanoma Patient Network Europe

Managing the Implications of Precision Medicine Advancement for Healthcare Professionals
  • Assessing the infrastructure, data and technology changes required to current healthcare systems in order to deliver a precision medicine approach
  • Examining the impact on the healthcare professional (HCP) and their role:
    • how do HCPs need to adapt to deliver the healthcare of the future?
    • effectively managing increasing patient empowerment
  • Communicating and convincing HCPs of the validity and potential of new personalised treatments and therapies
  • Developing and implementing precision medicine training programmes for healthcare professionals

 Erik Jylling, Executive Vice President, Danish Regions

Panel & Audience Discussion: Best Practice Strategies for Advancing Precision Medicine in Clinical Practice

This final Q&A discussion session will look at the challenges discussed previously around translating academic and laboratory research into clinical practice and give delegates the opportunity to share their own thoughts and experiences on what is needed to make precision medicine a reality. Is it down to changes in regulation and healthcare systems, or do we need to create a more open dialogue between academia, clinicians and patients to create better flexibility, foster innovation and deliver progress.

Closing Remarks from the Chair and Close of Conference
With Special Thanks to Our Sponsors, Exhibitors and Partners
© Precision Medicine Forum